Cemiplimab's proposed EU regimen could cut Libtayo infusion visits from every 3 weeks to every 6 weeks, trimming infusion time by up to half.
|Articles|September 25, 2017
ISPE 2017 Annual Meeting & Expo Keynote Speakers Announced
Author(s)BioPharm International Editors
Keynote speakers for ISPE’s 2017 Annual Meeting & Expo include representatives from AstraZeneca and GSK.
Advertisement
On Sep. 21, 2017, the International Society for Pharmaceutical Engineering (ISPE) announced the keynote speakers for its 2017
The ISPE keynote speakers include:
- Pam P. Cheng, executive vice president of global operations and IT for AstraZeneca; her presentation focus will be on manufacturing operations and specific aspects of the process.
- Roger Connor, president of global manufacturing and supply for GlaxoSmithKline; his presentation will explore how industries outside the pharmaceutical industry can influence its manufacturing approach.
- Enno de Boer, PhD, partner and leader of digital manufacturing North America for McKinsey & Company, an international management consulting firm, in addition to global leader for McKinsey’s digital capability center; his presentation will discuss digital manufacturing and its future influence.
- Glenn F. Pierce, a member of the board of directors of the World Federation of Hemophilia and an independent consultant, entrepreneur-in-residence at Third Rock Ventures; his presentation will concentrate on innovations and consequences related to hemophilia treatments.
Source:
Advertisement
Related to this article
The Skyrizi approval pairs an interleukin-23 antibody with an on-body injector for 720 mg subcutaneous induction in adults, per phase 3 AFFIRM data.
Gilead agrees to acquire PepStar’s oral IL-23R peptide program for $1.275 billion, Zymeworks licenses its DLL3-targeted trispecific T-cell engager ZW209 to Roche, and the US Treasury proposes adding biotechnology to its outbound investment restrictions.
FNIH CEO Dr Julie Gerberding will open the October 25-28 meeting with a talk on using AI, adaptive trials, and alternative methods in drug development.
Insilica's Dr Thomas Luechtefeld argues process traceability, not benchmark accuracy alone, determines whether AI toxicology decisions can be trusted.
Phase 1 HCXT-2001, an oral macrocyclic IL-23R peptide, could be paired with emvistegrast as a daily oral IBD treatment, according to Gilead.
Roche gains exclusive global rights to ZW209, a DLL3×CD3×CD28 trispecific T-cell engager designed for CD28 co-stimulation. A phase 1 study in small cell lung cancer and other neuroendocrine tumors is underway.
A Treasury proposed rule would restrict certain US investments in biotechnology in China and other countries of concern, raising questions about how cross-border licensing and joint venture deals will be treated.
Advertisement
Advertisement
Trending on BioPharm International
1
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
2
BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial
3
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
4
Gilead to Buy Oral IL-23R Peptide HCXT-2001 for $1.275 Billion
5